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Cytomegalovirus (CMV) retinitis is a late complication of organ and hematopoietic stem cell transplant,
the risk of which depends on the degree of immunosuppression. With the institution of preemptive
ganciclovir therapy early after transplant, most patients survive episodes of life-threatening CMV
infection during the early months (usually the ﬁrst 3 months) after transplant and hence late onset of
CMV disease, such as CMV retinitis, is being recognized more frequently. Direct involvement of the
macula or optic head remains the leading cause of visual loss in patients with CMV retinitis, but there are
few studies investigating the management of this condition.
Herein, we present the case of 28-year-old man who had acute myeloid leukemia and developed CMV
retinitis with bilateral cystoid macular edema and optic swelling in the right eye 6 months after bone
marrow transplant. He received treatment with intravitreal methotrexate in the right eye in combination
with oral valganciclovir. Visual acuity improved 1 month after four weekly injections of intravitreal
methotrexate 400 mg/0.1 mL. Resolved disc swelling and regression of macular edema were also
observed. By comparing binocular outcome, we present our ﬁndings and discuss the possible efﬁcacy and
safety of this treatment with respect to regression of anatomical damage and improvement in visual
acuity.
Copyright © 2015, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cytomegalovirus (CMV) is a double-stranded DNA virus
belonging to the human herpesvirus family, which includes herpes
simplex virus, varicella zoster virus, and EpsteineBarr virus. Clin-
ical characteristics of systemic CMV infections were initially
described in 1905.1f interest and no proprietary
logy, Chang Gung Memorial
d, PuTzu City, Chiayi County
ang).
iety of Taiwan. Published by ElseviHuman immunodeﬁciency virus (HIV) infection is the most
common cause of immunosuppression leading to reactivation of
CMV and symptomatic infection. Severe CMV infection has also
been associated with congenital immunodeﬁciency syndromes,
pharmacologic immunosuppression, organ transplantation, ma-
lignancy, and autoimmune disorders.2 CMV infection is the leading
viral cause of morbidity and mortality in patients receiving he-
matopoietic stem cell transplants (HSCTs) or solid organ trans-
plants (SOTs).3
One of the major targets of CMV infection is the retina.4
Although the virus was long known as a human pathogen, CMV
infection of the retina was not described until the 1950s.5 CMV was
proven to be the causative agent in presumed CMV retinitis in
1964.6 CMV retinitis was the AIDS-deﬁning diagnosis in about 5% ofer Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
Figure 1. Classic changes of cytomegalovirus retinitis appeared as areas of yellow-
white necrosis with vascular sheathing along the distribution of retinal vessel of (B)
the superior arc in the left eye and (A) both superior and inferior arcs in the right eye.
Exudates and edema were also noted with variable amounts of associated brushﬁre
pattern hemorrhage. Vitreous inﬂammation was mild and zone 1 involvement was
showed in both eyes. Optic disc swelling was also noted in the right eye, which had
worse visual acuity. (For interpretation of the references to color in this ﬁgure legend,
the reader is referred to the web version of this article.)
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CMV retinitis; however, the pediatric population is at a higher risk.8
After HSCT, the only large study published on CMV retinitis
development showed an incidence of 1.4% in patients who were
alive 100 days post-transplant.9
CMV retinitis is bilateral in approximately one third of pa-
tients.10 It is a relentless, slowly progressive infection, which, if not
treated, may result in blindness caused by total retinal necrosis,
retinal detachment, optic nerve involvement, or a combination of
several of these factors. Immune-mediated vascular damage may
also play a role in vasculitis.
Immediate, acute loss of central vision early in the disease
course rarely occurs.11 The causes of severe central visual loss
include CMV infection of the macular or optic nerve, macular se-
rous exudation, and cystoid macular edema (CME). CMV can either
infect the optic nerve directly or by extension from adjacent reti-
nitis.12 In the former case, optic neuritis with profound, irreversible
visual loss usually develops. With CMV infection involving the disc
or macular retina, an exudative neurosensory detachment develops
around the optic nerve, macula, or both, oftenwith the formation of
a macular star of consisting of lipid exudation.13
Previous results showed that ganciclovir alone (systemic or
intraocular administration) is less effective for CME in CMV retinitis
probably because of the inﬂammatory processes associated with
CME. CME tends to develop late in the clinical course, such as in the
setting of resolving CMV retinitis in non-HIV patients14 and in the
case of immune-reconstitution syndrome in HIV patients.15 Anti-
inﬂammatory or immunomodulatory agents, in addition to ganci-
clovir, may be considered in such situations.
The present case is of a patient with adult acute myeloid leu-
kemia who developed CMV retinitis with bilateral CME and asso-
ciated subretinal ﬂuid 6 months after HSCT. Optic swelling was also
observed in the right eye. Hesitant to receive intravitreal ganci-
clovir injections twice a week in both eyes, he accepted treatment
with less frequent intravitreal injection of methotrexate (MTX)
once a week in his right eye (which had more severe symptoms) in
combinationwith oral valganciclovir.With comparison of binocular
outcome, we present our ﬁndings and discuss the possible efﬁcacy
and safety of this therapy for regression of macular damage and
improvement in visual acuity.
2. Case Report
A 28-year-old man had acute myeloid leukemia, M2 (Chr: 46,XY
{6}; MLL-PTD[e], NPM1[e], FLT3-ITD[e]) and completed chemo-
therapy in June 2012. He had a relapse 1 year later and received
reinduction chemotherapy in June 2013 and bone marrow trans-
plant in November, 2013. CMV disease with gastrointestinal
manifestationwas diagnosed 7 weeks later by the detection of CMV
DNA in plasma samples using real-time polymerase chain reaction
(PCR). The patient received antiviral treatment with intravenous
(IV) ganciclovir 450 mg (5 mg/kg) twice daily for 2 weeks until two
consecutive samples of plasma negative for CMV PCR were
obtained.
In May 2014, he was referred to our clinic as he had been
experiencing deteriorating vision in both eyes for 2 weeks. At the
ﬁrst visit, his best corrected visual acuity was counting ﬁngers at
20 cm (2 logMAR units) in his right eye (OD) and 20/100 (0.3 log-
MAR units) in his left eye (OS).
Slit-lamp biomicroscopic examination of the anterior chamber
in OS yielded normal results, whereas a 1þ anterior chamber
cellular reaction was observed in OD. On indirect ophthalmoscopy,
changes typical of CMV retinitis were observed, such as areas of
yellowewhite necrosis with vascular sheathing along the distri-
bution of retinal vessels of the superior arc in OS and both thesuperior and inferior arcs in OD. Exudates and edema were also
noted with varying degrees of hemorrhage, which presented with a
brushﬁre pattern. Optic disc swelling was also noted in OD, which
had worse visual acuity. Vitreous inﬂammation was mild in both
eyes (Figure 1).
Optical coherence tomography showed CME with subretinal
ﬂuid in both eyes (Figure 2). Central macular thickness was 508 mm
OD and 567 mmOS. On laboratory examination, CMVwas identiﬁed
in the aqueous humor of both eyes using PCR. The patient's
hemograms revealed a relative immunocompetent status 1 month
before and after he visited our clinic; however, PCR results for
plasma CMV infection were positive again at that time.
CMV retinitis with right optic neuritis and bilateral macular
edema was diagnosed. Since the patient was hesitant to accept
frequent intravitreal injections of ganciclovir, it was decided to
administer oral valganciclovir with an induction dose of 900 mg
twice a day for 3 weeks and aweekly adjuvant intravitreal injection
of MTX 400 mg/0.1 mL unilateral in OD, the more severely affected
eye, for 1 month.
Best corrected visual acuity improved to 20/400 (1.3 logMAR
units) after four MTX injections and to 20/63 (0.5 logMAR units) OS
a month later. Indirect ophthalmoscopy revealed resolving disc
swelling in OD (Figure 3) and follow-up optical coherence tomog-
raphy revealed that macular edema had subsided in MTX-injected
eyes, but persisted OS (Figure 4). A maintenance dose of valganci-
clovir 900 mg orally once a day was continued. No recurrence of
Figure 2. The optical coherence tomography showed cystoid macular edema with
subretinal ﬂuid in (A) the right eye and (B) the left eye.
Figure 4. Four weeks after treatment, the optical coherence tomography follow-up
showed that macular edema (A) subsided in intravitreal methotrexate-injected eyes
but (B) persisted in the left eye.
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the next 8 months of follow up.
3. Discussion
In immunosuppressed patients, retinitis can result from hema-
tological dissemination of reactivated CMV as well as from exoge-
nously acquired CMV. Although CMV retinitis is the most common
clinical complication of CMV reactivation in HIV-infected patients,
it is only infrequently reported in HSCT recipients. However, pre-
emptive ganciclovir therapy early after transplant16 allows mostFigure 3. The color fundus picture showed resolving disc swelling in the right eye 4
weeks after treatment. (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of this article.)HSCT recipients to survive life-threatening CMV infection during
the early months (usually the ﬁrst 3 months) after transplant, and
hence late onset of CMV disease is being recognized more
frequently.
In a study by Crippa et al,8 CMV retinitis was found to be a late
complication of HSCT and was mainly seen in patients with ante-
cedent CMV reactivation or disease. The median time of diagnosis
of CMV retinitis was 251 days (range, 106e356 days). Similarly, our
patient presented with CMV viremia with gastrointestinal mani-
festationwithin 7weeks of HSCT, and developed visual symptoms 6
months after HSCT.
At onset, CMV retinitis may show only a few symptoms,
providing scant evidence of the infection's potential to cause severe
visual loss.9 The presence of symptoms is often related to the retinal
location involved. CMV retinitis affecting the posterior pole is more
often symptomatic than peripherally located retinitis. Silverstein
et al13 reported prominent loss of vision associated with CME in
seven eyes with CMV retinitis in AIDS patients. In each patient, the
area of retinitis involved zone 1. Our patient also showed zone 1
involvement in both eyes, which was indicative of the development
of worse macular complications. Furthermore, CMV papillitis, a
very unusual complication of CMV infection causing disc swelling
and less reversible visual loss, has even been reported in an
immunocompetent patient. In our patient, optic disc swelling
resolved after 1 month of therapy, but with sequelae of occluded
retinal vessels. Immune-mediated vascular damage may play a role
in papillitis. As in our case, this patient too did not seek medical
treatment until severe vision loss caused by macular and papillary
involvement occurred.
Ganciclovir is an acyclovir analog and was the ﬁrst antiviral
agent to be approved for the treatment of CMV disease; it remains
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transplant recipients.17 The incidence of CMV disease occurring
within the ﬁrst 100 days post-transplant was signiﬁcantly less with
ganciclovir compared to placebo18 and patients receiving ganci-
clovir had signiﬁcantly greater overall survival than the placebo
group at both 100 days and 180 days post-transplant.19
IV ganciclovir (Cytovene-IV, Roche, Basel Switzerland) was
approved in 1989 for treating CMV retinitis in AIDS patients. To
circumvent the risks and inconvenience associated with the use of
an indwelling catheter for IV administration, an oral formulation
was developed. Oral ganciclovir represented a major advance in
maintenance therapy and prophylaxis in case of CMV retinitis.
However, the low bioavailability (approximately 5%) and the high
pill burden from the TID regimen are signiﬁcant limitations. Based
on the model exempliﬁed by valacyclovir, a prodrug was developed
to improve the bioavailability of oral ganciclovir. Valganciclovir has
an oral bioavailability of around 60%. It was approved in 2000 for
the treatment of CMV retinitis in AIDS patients and was later
approved for the prophylactic treatment of CMV in certain SOT
recipients. Once-daily oral administration of valganciclovir 900 mg
provides systemic exposure to ganciclovir that is equivalent to that
provided by once-daily administration of IV ganciclovir 5 mg/kg.
Besides systemic ganciclovir, intravitreal injection/implant of gan-
ciclovir in the affected eye is also signiﬁcantly efﬁcacious in treating
CMV retinitis. The elimination half-life of ganciclovir from the vit-
reous humor after intravitreal injection was estimated to be 13.3
hours in CMV retinitis patients. Intravitreal ganciclovir concentra-
tions were estimated to remain above the ID50 (average 0.66 mg/mL)
of the virus for about 62 hours after a single 200 mg intravitreal
dose.20 In clinical practice, injections are given two or three times
per week during the induction phase, followed by once a week
injections during long-term maintenance therapy. Frequent intra-
vitreal injections appear to be a burden, as exempliﬁed by the
hesitation of the patient in our case. Patients treated with an
intravitreal injection and implant alone are also at a signiﬁcantly
greater risk of developing CMV disease in the contralateral eye or in
other organs.21
Although CMV retinitis patients, especially those with only
midperipheral lesions, have shown a good response to IV ganci-
clovir or oral valganciclovir treatment, complicated macular and
papillary lesions have less favorable prognosis with these formu-
lations according to current studies.12e15 Previous results have
shown that ganciclovir alone is less effective for CME in CMV
retinitis probably because of the high inﬂammatory component of
CME. CME can even developed in the setting of resolving CMV
retinitis in non-AIDS patients.14 It also causes vision loss as a result
of immune-recovery syndrome in HIV patients with a history of
CMV retinitis on highly active antiretroviral therapy.15 Our patient's
hemograms showed relative immunocompetence during the
ocular disease course. It is likely that he delayed seeking medical
help until severe visual impairment occurred, when he was under
an immune reconstitution status. Intravitreal injection of steroids
seems a reasonable approach to treat the inﬂammation associated
with macular edema and papillitis in CMV retinitis. However, CMV
reactivation is a big concern.
MTX is a competitive inhibitor of dihydrofolate reductase. It has
immunomodulatory and antiproliferative (antineoplasm) proper-
ties through multiple mechanisms. One of its major anti-
inﬂammatory actions is inhibition of aminoimidazole carbox-
amide ribonucleotide transformylase/IMP cyclohydrolase resulting
in increased intracellular and extracellular adenosine, which is a
potent inhibitor of inﬂammation and modulates cell trafﬁcking.22
Adenosine also suppresses the action of proinﬂammatory media-
tors tumor necrosis factor-a, interleukin (IL)-6, IL-8, macrophage
inﬂammatory protein-1a, leukotriene B4, and nitric oxide, andenhances the production of the anti-inﬂammatory mediators IL-10
and IL-1 receptor antagonists. Ultimately, adenosine leads to the
resolution of inﬂammation by downregulating macrophage acti-
vation and promoting a shift from a TH1 to a TH2 response.23 Sys-
temic MTX has been included in many standard treatments for a
variety of malignancies.24 It is also a commonly used steroid-
sparing agent for the treatment of systemic inﬂammatory disor-
ders, such as systemic lupus erythematosus, rheumatoid arthritis,
psoriasis, and a range of noninfectious uveitides.25 Various
ophthalmic inﬂammatory conditions response to intravitreal MTX
therapy, and intraocular lymphomas associated with primary cen-
tral nervous system lymphoma have been effectively and safely
treated with intravitreal injections of MTX. A 400 mg concentration
of MTX in human eyes appears to be clinically well tolerated.26 The
half-life of MTX in vitreous ﬂuid was estimated to be 12.4e21.5
hours by assuming ﬁrst-order elimination kinetics. Although the
concentration was still high 24 hours after intravitreal injection
(69.94e82.89mM), there was no ocular toxicity. A single intravitreal
injection of 400 mg of MTX yielded antineoplasm levels in the vit-
reous for more than 72 hours.27 A MTX 400 mg/0.1 mL weekly in-
jection is universally applied in eyes with primary intraocular
lymphoma. Moreover, in eyes with uveitis and CME, a single or few
injections are highly curative. A study documented 76% control of
inﬂammation and 56% corticosteroid-sparing effect in patients with
various ocular inﬂammatory conditions treated with MTX.28
Hardwig et al reported retention of visual acuity in 12 of 16 study
eyes with conditions other than primary intraocular lymphoma
after one single injection.29 Taylor et al reported that 67% (10/15) of
patients with uveitic CME responded to treatment at 1 month and
87% (13/15) by 3months after one single injection. Themedian time
to relapse was 4 months.30 In our patient, the macular edema in OD
responded rapidly to weekly intravitreal MTX 400 mg/0.1 mL in-
jections for 1 month compared with the other eye, mainly due to
the anti-inﬂammatory action and downregulation of macrophage
activation by MTX. Moreover, the papillitis also underwent remis-
sion, although this might have been achieved by the induction
treatment of oral valganciclovir alone.
The macular edema in OD did not recur after four intravitreal
injections of MTX, while that in the OS persisted during the 8-
month follow up. No ocular side effects were observed in the MTX-
injected eye. Our case revealed the possible efﬁcacy and safety of
MTX as a corticosteroid-sparing adjuvant intravitreal injection in
combination with valganciclovir (which has high oral bioavail-
ability) for macular edema and for improving visual acuity. Further
studies are needed to conﬁrm our results.
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